CONSOLIDATED QUARTERLY FINANCIAL DATA - UNAUDITED (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended								6 Months Ended	12 Months Ended
	Jan. 16, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Information Disclosure [Abstract]
Total revenues		$ 89,707	$ 84,131	$ 78,109	$ 75,804	$ 88,122	$ 122,238	$ 146,254	$ 117,387		$ 327,751	$ 474,002	$ 495,769
Gross profit		46,386	63,026	53,819	57,327	59,406	75,749	69,478	53,475
Operating expenses		240,329	81,050	169,662	175,024	78,241	95,084	27,591	104,239
Net loss from continuing operations		(199,928)	(23,617)	(120,827)	(122,084)	(20,746)	(64,678)	(25,817)	(58,098)		(466,456)	(169,339)	(205,153)
Net income (loss) from discontinued operations		0	0	0	0	(1,531)	95,517	5,736	3,856		0	103,578	5,925
Net loss		$ (199,928)	$ (23,617)	$ (120,827)	$ (122,084)	$ (22,277)	$ 30,839	$ (20,081)	$ (54,242)		$ (466,456)	$ (65,761)	$ (199,228)
Basic and diluted earnings per share:
Loss from continuing operations (in dollars per share)		$ (5.89)	$ (0.70)	$ (3.57)	$ (3.54)	$ (0.60)	$ (1.88)	$ (0.75)	$ (1.70)		$ (13.71)	$ (4.92)	$ (5.88)
Income (loss) from discontinued operations (in dollars per share)		0	0	0	0	(0.04)	2.77	0.17	0.11		0	3.01	0.17
Total (in dollars per share)		$ (5.89)	$ (0.70)	$ (3.57)	$ (3.54)	$ (0.64)	$ 0.89	$ (0.58)	$ (1.59)		$ (13.71)	$ (1.91)	$ (5.71)
Condensed Financial Statements, Captions [Line Items]
Restructuring expenses					$ 7,400						$ 7,420	$ 0	$ 0
Impairment of intangible assets		$ 151,300
Makena
Condensed Financial Information Disclosure [Abstract]
Total revenues											122,064	322,265	$ 387,158
Makena | Developed technology rights
Condensed Financial Statements, Captions [Line Items]
Impairment of intangible assets				$ 77,400						$ 77,400
Makena Auto-Injector, Intrarosa And Vyleesi Products | Developed technology rights
Condensed Financial Statements, Captions [Line Items]
Impairment of intangible assets											$ 155,000
Contingent Consideration
Condensed Financial Statements, Captions [Line Items]
Adjustments to fair value of contingent consideration								$ 49,800				$ 49,600
Perosphere Pharmaceuticals Inc.
Condensed Financial Statements, Captions [Line Items]
In process research and development acquired	$ 74,900				$ 74,900